Over the past several decades, the rate at which new antimicrobial therapies have been discovered has steadily declined, while the prevalence of antibiotic resistant bacteria has simultaneously risen.^[@ref1],[@ref2]^ The inherent bactericidal and/or bacteriostatic nature of antibiotics inevitably leads to resistance;^[@ref3]^ therefore, considerable recent research has focused on potential approaches that diminish bacterial pathogenicity without affecting bacterial growth.^[@ref4],[@ref5]^ By modulating bacterial cell-to-cell communication, a process termed quorum sensing (QS), many virulence phenotypes in pathogens can be attenuated without affecting bacterial viability.^[@ref6]−[@ref9]^ Our laboratory^[@ref10]−[@ref19]^ and others^[@ref20]−[@ref27]^ have become actively involved in the design of small molecule and peptidic tools capable of inhibiting QS in bacteria and exploring the roles of this signaling process in infection.

Bacteria use QS to act more as a multicellular group instead of as individual isolated cells.^[@ref6]−[@ref8]^ This communication system involves the production of diffusible chemical signals that increase in concentration proportionally to population expansion. Once a threshold signal density is reached, the molecules can productively bind to transcription factors that alter gene expression levels.^[@ref6],[@ref7]^ In many pathogenic bacteria, QS coordinates the expression of virulence factors that are effective only when produced at high population densities on a host. The canonical QS circuit in Gram-negative bacteria is the LuxI/LuxR system, first characterized in the luminescent symbiont *Vibrio fischeri*.^[@ref8]^ This system consists of a LuxI-type synthase that produces an *N*-acyl [l]{.smallcaps}-homoserine lactone (AHL) chemical signal, which in turn binds a cognate intracellular LuxR-type receptor ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The AHL signal can passively diffuse into and out of the cell (certain bacteria also use active export).^[@ref12]^ AHL:LuxR-type receptor binding at high cell densities typically promotes receptor homodimerization, binding to specific QS promoters, and the transcriptional regulation of group beneficial genes.

![General schematic outlining the mechanism of Gram-negative quorum sensing. LasI/LasR are LuxI/LuxR homologues in *P. aeruginosa*. Blue double oval is an enlarged view of one bacterium.](id-2015-00112s_0002){#fig1}

*Pseudomonas aeruginosa* is associated with infections in patients with cystic fibrosis, immunocompromised individuals (e.g., patients with HIV), and chronic wounds.^[@ref28],[@ref29]^ This Gram-negative opportunistic pathogen has a relatively complex QS network consisting of two LuxI/LuxR pairs (LasI/LasR and RhlI/RhlR), a LuxR orphan receptor (QscR, i.e., lacking an associated synthase), and the *Pseudomonas* quinolone signal (PQS), an alkylquinolone that binds to PqsR (a LysR-type transcriptional regulator).^[@ref10],[@ref30]^ QS regulates about 10% of the *P. aeruginosa* genome,^[@ref31]^ and these transcriptional changes enable the bacterial population to overwhelm the host's defenses. Activation of LasR by its cognate ligand (*N*-(3-oxo-dodecanoyl) [l]{.smallcaps}-homoserine lactone (OdDHL), [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) up-regulates many virulence phenotypes (e.g., protease production and biofilm formation) and can lead to positive regulation of the Rhl and Pqs systems, placing LasR atop the QS hierarchy in a variety of environmental contexts.^[@ref10]^ For this reason, considerable work has focused on designing small molecules and macromolecules that inhibit LasR activity^[@ref10]−[@ref12],[@ref17],[@ref18],[@ref25],[@ref27],[@ref32]−[@ref36]^ and thereby inhibit associated virulence phenotypes in *P. aeruginosa*. Notable in this regard are contributions by Bassler,^[@ref27]^ Greenberg,^[@ref35],[@ref36]^ Meijler,^[@ref20],[@ref21]^ Spring,^[@ref22]−[@ref25],[@ref37]^ and co-workers focused on novel small molecule ligands for LasR and by Janda and co-workers^[@ref34],[@ref38]^ focused on antibodies that bind OdDHL and sequester it from LasR.

Our laboratory has developed a variety of small molecule LasR antagonists to date.^[@ref10]−[@ref12],[@ref17],[@ref18],[@ref32],[@ref39],[@ref40]^ Most of these efforts have focused on synthesizing compounds that maintain the homoserine lactone (HSL) headgroup while changing the acyl tail to various chemotypes. These modifications have resulted in the discovery of numerous non-native AHL antagonists of LasR with IC~50~ values from ∼0.25 to 100 μM. Although these AHLs can be used to attenuate virulence phenotypes in *P. aeruginosa* and represent some of the most potent LasR modulators known, they are beset by a number of shortcomings.^[@ref24],[@ref25]^ Namely, the HSL headgroup is prone to hydrolysis in aqueous media (rendering the compounds inactive), and AHLs also can be readily degraded by bacterial and host lactonases and acylases.^[@ref37],[@ref41]−[@ref43]^ This chemotype is also actively exported from *P. aeruginosa* via the MexAB-OprM efflux pump.^[@ref12]^ Further confounding their use, many of our most potent LasR antagonists exhibit a non-monotonic dose--response curve when tested in cell-based reporter assays measuring LasR transcriptional activity.^[@ref18]^ Specifically, we observe that these compounds are capable of LasR antagonism at low concentrations, whereas at high concentrations we observe LasR agonism instead. We are currently delineating the mechanistic origins of this non-monotonic effect^[@ref44]^ and speculate that these compounds interact with either another site on LasR or other targets at high (μM) concentrations that permit LasR activation. No matter the origin of this effect, LasR antagonists that do not display this dose--response feature are certainly desirable as research tools. Identifying such compounds, and ideally ones not prone to hydrolysis, was a main goal of the current study.

To design new LasR antagonists that would avoid the limitations of our previous AHL leads, we utilized a structure-based scaffold-hopping approach. Triphenyl derivative TP1 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), discovered in a high-throughput screen by Greenberg and co-workers,^[@ref35]^ was reported as a LasR agonist with equivalent if not enhanced potency compared to LasR's native ligand, OdDHL ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), in cell-based assays.^[@ref45]^ We identified TP1 as an excellent candidate for further evaluation because of its remarkable potency, its enhanced stability to hydrolysis compared to OdDHL,^[@ref35]^ its low MexAB-OprM efflux pump susceptibility,^[@ref44]^ and its modular structure that is readily amenable to synthetic modification. We hypothesized that by uniting the 2-nitrophenyl "headgroup" of TP1 with various tail motifs common to our AHL-based inhibitors, we could generate novel hybrid compounds capable of LasR antagonism. Indeed, recent work by Perez and co-workers on irreversible LasR inhibitors based on TP1 is supportive of the conversion of this scaffold from LasR agonist to LasR antagonist.^[@ref46]^ Through the synthesis and biological evaluation of a focused library based on this chemotype, we demonstrated that compounds of this new hybrid structure are capable of either agonizing or antagonizing LasR. Moreover, several new LasR antagonists with single-digit micromolar potencies were identified. Among these, one compound (**17**) emerged with an optimal combination of potency and maximum efficacy. More notably, this compound lacked a non-monotonic antagonism dose--response curve, demonstrating its potential utility as a tool compound. Finally, we compared the chemical stability of the new compounds to that of their HSL-containing congeners and confirmed that the hybrid compounds exhibited greatly enhanced chemical stability over a range of pH values.

![(A) Structures of the native LasR agonist OdDHL and non-native LasR agonist TP1. (B) Overlay of the ligand-binding sites in the OdDHL:LasR (pink) and TP1:LasR (green) X-ray crystal structures with many of the key hydrogen bonds indicated (dashed yellow lines). OdDHL is peach, and TP1 is cyan. Structures are from PDB IDs 3IX3 and 3IX4, respectively. (C) Two-dimensional view of the key hydrogen bonds between LasR and agonists OdDHL and TP1. (D) Illustration of our scaffold-hopping mode-switching approach, installing a *p*-bromo phenethyl amine on the TP1 headgroup to mimic known AHL-derived LasR antagonist **1**.](id-2015-00112s_0003){#fig2}

Results and Discussion {#sec2}
======================

We began our study by analyzing the reported X-ray crystal structures of the LasR N-terminal ligand binding domain with TP1^[@ref47]^ and with OdDHL^[@ref48]^ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). Congruent with the past study by Zou and Nair,^[@ref47]^ we determined that the 2-nitrophenyl ring of TP1 closely mimics the HSL headgroup in OdDHL, with both chemotypes making the same network of hydrogen-bonding contacts in the LasR ligand-binding site ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). Because prior studies by our laboratory have demonstrated that the LasR agonist OdDHL can be "mode switched" to a LasR antagonist by replacing the native 3-oxo-dodecanoyl tail with alternate non-native groups (mostly aryl, such as **1** in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D),^[@ref16],[@ref18]^ we hypothesized that the same "mode-switching" phenomenon could be possible with the nonhydrolyzable 2-nitrophenyl headgroup of TP1. Accordingly, by considering structure--activity relationships (SARs) previously determined for LasR using AHL analogues, we reasoned that combining tails from known active AHL antagonists with the 2-nitrophenyl headgroup could yield novel LasR antagonists.^[@ref16]−[@ref18]^ We note that while we have previously examined related hybrid AHL analogues, with non-native headgroups and known active aryl tails,^[@ref40]^ these compounds had only limited activity in LasR. The structural data demonstrating the strong overlap of the TP1 2-nitrophenyl headgroup with that of the HSL strengthened our enthusiasm for exploring the activity of the new hybrid class of LasR modulators proposed here.

To test our strategy, we first designed a focused library of 28 hybrid compounds combining the 2-nitrophenyl headgroup with a variety of acyl groups that could presumably sample the chemical space in the LasR ligand-binding site usually occupied by the tail region of OdDHL (as judged by our analysis of the OdDHL:LasR structure) and/or have previously been shown to strongly modulate LasR when incorporated into AHLs.^[@ref16]−[@ref18]^ These compounds were readily prepared by reacting 2-nitrobenzoyl chloride with various amines in dichloromethane with Hünig's base ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). After compound purification, the library was evaluated for LasR agonism and antagonism using an *Escherichia coli* strain that contains a LasR expression plasmid and reports LasR activity via β-galactosidase production through a promoter fusion (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf) for details).^[@ref18]^

We began by screening the library for LasR agonism at 50 μM. Among the various chemotypes represented, we anticipated that compound **28** would show LasR agonism, because it contained a tail similar in length to that of OdDHL. The primary screen revealed *m*-nitro compound **19** and, as anticipated, **28** as LasR agonists, whereas the remaining compounds were inactive. Dose--response analyses using the *E. coli* reporter strain revealed that **19** and **28** agonized LasR with EC~50~ values of 25 and 0.36 μM, respectively (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf)). We note that these agonists are considerably less active than TP1 and OdDHL (each with EC~50~ values of \<5 nM in this strain). Nevertheless, this result demonstrated that hybrid compounds that combine the 2-nitrophenyl headgroup with chemical moieties distinct from TP1 can act as LasR modulators. It is interesting that the other library members with structures very similar to **19** and **28** failed to agonize LasR, which suggests that the tail groups in **19** and **28** may be capable of making specific contacts with LasR that serve to stabilize the active protein. LuxR-type proteins are known to be highly selective for agonist-type ligands, whether native or non-native,^[@ref19]^ and these data for LasR match this trend.

![Synthesis of the Hybrid Compound Library\
All compounds had purities ≥95%; see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf) for full characterization data.](id-2015-00112s_0006){#sch1}

We next evaluated the library in a primary LasR antagonism screen at 50 μM in competition against OdDHL (at 5 nM; see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf)). Many of the compounds showed strong antagonism of LasR at this concentration ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), demonstrating that this hybrid scaffold was poised for LasR antagonism. Examination of the assay data revealed some interesting SAR trends for LasR antagonism by compounds with benzylamine-derived tails. Specifically, halogen substitution at the meta position of the aryl tail engendered efficacious LasR inhibition at 50 μM (e.g., compounds **4**, **6**, **8**, **10**, **13**, and **14**). Compounds that contained this functionality had an average LasR antagonism of 48%, whereas those lacking it averaged only 23% antagonism. This SAR trend mirrors our previous observation that meta-substitution on the aryl groups of phenylacetyl HSL analogues (i.e., PHLs) engendered strong LasR antagonism.^[@ref18]^ In addition, we found that the one-carbon longer hybrid homologues derived from phenethylamine, most notably *p*-bromo derivative **17**, showed LasR inhibitory activity. These single-point assay data encouraged us to evaluate hybrid compounds with ∼40% LasR antagonism for potency.

![Primary antagonism data for the hybrid compound library in the *E. coli* LasR reporter strain. Compounds were evaluated at 50 μM in the presence of an EC~70~ of OdDHL (5 nM). Culture treated with only 5 nM OdDHL was set to 0% antagonism/100% activity. Culture treated with only DMSO was set to 100% antagonism/0% activity (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf) for full assay details).](id-2015-00112s_0004){#fig3}

After generating antagonism dose--response curves, we noted that IC~50~ values for the selected compounds ranged from 4.8 to 52 μM and maximum antagonism (i.e., efficacy) ranged from 41 to 78% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). These data further highlighted the SAR describing the heightened activity of compounds containing meta-halogenated phenyl rings linked to the 2-nitrophenyl headgroup (e.g., **4**, **6**, **8**, **10**, **13**, and **14**). Indeed, these compounds exhibited an average IC~50~ of 12 μM. Compounds without this structural moiety, on the other hand, had an average IC~50~ of 31 μM. Interestingly, the *o*-nitro compound (**18**), a regioisomer of the *m*-nitro LasR agonist **19** noted above, showed strong LasR antagonism instead (IC~50~ = 9.7 μM). Many of the most potent compounds, however, displayed a slight to moderate non-monotonic dose--response that is usually characteristic of potent AHL-derived LuxR-type receptor antagonists.^[@ref18]^ Specifically, compounds **6**, **10**, and **13** showed substantial curve inversion to LasR agonism at concentrations \>100 μM, whereas compound **14** exhibited a very slight LasR agonism upturn at 250 μM (see curves in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf)). Furthermore, maximum efficacy for **6**, **10**, **13**, and **14** was modest and averaged 56% antagonism. However, *p*-bromo compound **17**, based on aryl AHL analogue **1** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D), defied these two trends. In fact, **17** displayed no non-monotonic characteristics, was the most potent LasR antagonist identified in our focused library (IC~50~ = 4.8 μM), and had a maximum efficacy that was among the best (72%). As AHL **1** is one of our most potent reported LasR antagonists (in this *E. coli* reporter^[@ref44]^ and others^[@ref18]^), it follows that this scaffold-hopping approach on TP1 involving the same tail region could produce a potent LasR antagonist.

###### Potency and Maximum Efficacy Values for Selected Compounds in the *E. coli* LasR Reporter

  compd    IC~50~ (μM)[a](#t1fn1){ref-type="table-fn"}   95% CI (μM)[b](#t1fn2){ref-type="table-fn"}   max % antagonism[c](#t1fn3){ref-type="table-fn"}
  -------- --------------------------------------------- --------------------------------------------- --------------------------------------------------
  **4**    21                                            10--43                                        60
  **6**    6.6[d](#t1fn4){ref-type="table-fn"}           4.1--10                                       55
  **8**    16                                            10--25                                        58
  **9**    45                                            27--74                                        78
  **10**   9.0[d](#t1fn4){ref-type="table-fn"}           4.1--10                                       50
  **13**   9.6[d](#t1fn4){ref-type="table-fn"}           4.5--20                                       57
  **14**   6.5[d](#t1fn4){ref-type="table-fn"}           3.6--11                                       62
  **17**   4.8                                           3.2--7.0                                      72
  **18**   9.7                                           4.8--20                                       59
  **20**   35                                            21--59                                        41
  **24**   37                                            26--53                                        71
  **25**   21                                            12--37                                        72
  **27**   40                                            30--55                                        78
  **29**   52                                            32--84                                        72

Calculated by testing the compound's ability to abrogate LasR based activation of *lasI-lacZ* over a range of concentrations in the presence of 5 nM OdDHL.

CI = 95% confidence interval for IC~50~ value.

Denotes the lowest amount of LasR activity seen for individual compounds at any concentration throughout the curve. See the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf) for individual dose--response curves.

Dose--response antagonism curve shows inversion to agonism (i.e., non-monotonic behavior) at high compound concentrations. Concentrations at which LasR agonism was observed were excluded from IC~50~ calculations.

Looking more broadly at the library, when we compared the activities of these new hybrid compounds to our previously reported non-native AHL analogues that contain the same tail structures,^[@ref16]−[@ref18]^ the hybrid compounds consistently have slightly reduced potencies relative to the parent AHL analogues. To obtain more quantitative comparative data, we submitted the HSL-containing congeners of compounds **14**, **17**, and **25** to identical LasR antagonism assay conditions and found that the AHL congeners were 11-, 18-, and 2-fold more potent, respectively (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf) for dose curves of AHL compounds). However, the hybrid compounds displayed other beneficial qualities for use as probe molecules that offset this reduction in potency; we delineate these features below for compounds **14** and **17**.

In contrast to other potent hybrid compounds identified herein (e.g., **6**, **10**, and **13**), compounds **14** and **17** display only slight or no non-monotonic effects in their LasR antagonism curves, respectively. Accordingly, these compounds largely maintained their LasR inhibitory activities at high concentrations, an extremely desirable trait for probe compounds intended for use as QS inhibitors (e.g., if used at ∼10--50 times their IC~50~). In contrast, the AHL congeners of **14** and **17** elicit a strong non-monotonic effect that induces LasR agonism at higher compound concentrations (in both *E. coli* and *P. aeruginosa* reporter strains).^[@ref44]^ The dose--response curves of AHL analogue **1** and hybrid compound **17** explicitly illustrate this phenomenon ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, panel A vs panel B). Again, we are currently working to fully understand the mechanistic origins of such non-monotonic dose curves (for AHLs and certain hybrid compounds). With or without these mechanistic data, if one seeks to probe a system by antagonizing LasR and observing the downstream effects, AHL analogue **1** must be dosed carefully to ensure that LasR is not being unintentionally agonized ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). In contrast, antagonist **17** unambiguously causes LasR antagonism ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B), and this compound's maximum efficacy surpasses that of AHL analogue **1**. These features serve to showcase the value of **17** as a chemical tool to study LasR relative to AHL **1** and that one must look at characteristics beyond an IC~50~ value to best ascertain a compound's utility.

![LasR antagonism dose--response curves for AHL analogue **1** (A) and hybrid compound **17** (B) in the *E. coli* reporter. AHL analogues **1** and **30** decompose in aqueous buffers at pH 8 (C), 7 (D), and 6 (E), whereas hybrid compounds **14** and **17** are stable throughout the assay. Compound structures are shown in panel F. Compound concentrations were determined using HPLC referenced to an internal standard (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf)).](id-2015-00112s_0005){#fig4}

As highlighted above, another chemical liability of AHLs relative to other QS probe molecules is their hydrolytic instability,^[@ref37],[@ref41]−[@ref43]^ and we reasoned that hybrid compounds such as **14** and **17**, lacking the HSL headgroup, should be highly robust in aqueous media. The rate of AHL hydrolysis will of course be dependent on the medium type and assay conditions, and this can be affected by variable pH throughout the length of assays. Of direct interest to LasR, *P. aeruginosa* is known to preferentially metabolize weak carbon acids, which has been shown to increase the pH of standard culture (i.e., LB) media to approximately 8.5 over 48 h.^[@ref37]^ Therefore, we decided to evaluate the hydrolytic stabilities of compounds **14** and **17** over time in buffer solutions at pH 6, 7, and 8 and compare their stabilities to those of their AHL congeners (**30** and **1**, respectively; [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C--F). The compound solutions were incubated at 37 °C with shaking, and aliquots were examined every 2 h using high-performance liquid chromatography (HPLC).

As predicted from the literature,^[@ref35],[@ref37],[@ref41]−[@ref43]^ the AHLs decomposed at the fastest rate in a mildly alkaline buffer ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C), at a moderate rate in neutral buffer ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}D), and slowest under slightly acidic conditions ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}E). The HSL half-lives for AHLs **1** and **30** at neutral pH were between 8.5 and 11 h. Because many assays routinely last longer than 12 h, these data demonstrate that the concentration of active AHL will vary widely throughout an assay, providing an additional layer of complexity to designing the assay, analyzing data, and drawing conclusions. Furthermore, if the pH becomes slightly alkaline, which occurs regularly with *P. aeruginosa* cultures, HSL decomposition accelerates. The decomposition of **1** and **30** at pH 8 illustrates this point, as their half-lives decrease to between 2 and 3.5 h ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). In contrast, hybrid compounds **14** and **17** were highly stable under each buffer condition tested (blue lines, [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C--E), showing no decomposition. These results further emphasize the worth of such hybrid chemotypes as hydrolytically stable LasR modulators that can be used in a range of medium types, including slightly acidic or alkaline conditions. Although not evaluated here, we also predict that these non-AHL derived compounds should display enhanced stability toward bacteria- and host-derived enzymes known to degrade AHLs such as lactonases and acylases.^[@ref37],[@ref41]−[@ref43]^

In summary, we report herein our efforts toward the design of new QS modulators in *P. aeruginosa* with enhanced stabilities and activities for use as chemical tools. We outline a structure-based scaffold-hopping approach for the design of new synthetic ligands to modulate the *P. aeruginosa* QS receptor, LasR. We replaced the HSL headgroup with a 2-nitrophenyl fragment derived from the known LasR agonist, TP1, and combined that component with various tail regions of non-native AHL analogues known for LasR antagonism to generate a 28-member focused library. Screening of this library in an *E. coli* LasR reporter strain led to the discovery of many new LasR modulators, some of which displayed strong potency and efficacy as LasR antagonists. Compound **17** was the most valuable tool compound emerging from this study, with an IC~50~ of 4.8 μM and a maximum efficacy of 72%. Importantly, **17** does not display the non-monotonic LasR modulatory activity exhibited by known potent AHL analogues and other hybrid compounds identified in this library. Furthermore, this new hybrid chemotype also had greatly enhanced hydrolytic stability compared to HSL containing congeners. Ongoing studies will focus on improving compound potency, replacing the nitro group with an isosteric substitute resulting in compounds with greater in vivo tolerance,^[@ref49]^ and evaluation of these compounds in other LuxR-type receptors. These experiments will be reported in due course.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsinfecdis.5b00112](http://pubs.acs.org/doi/abs/10.1021/acsinfecdis.5b00112).Synthetic protocols and full compound characterization data, biological assay protocols, dose--response curves, and full details of compound stability studies. ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.5b00112/suppl_file/id5b00112_si_001.pdf))
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